'India, China to play key role in pharma industry's growth plans'

Image
BS Reporter New Delhi
Last Updated : Jan 20 2013 | 10:38 PM IST

Emerging economies like India and China will increasingly figure among the growth plans of leading multinational pharmaceutical companies, a global survey of top 15 pharma companies carried out by Ernst & Young said.

The report, released today, says the global drug firms are counting on emerging markets to extend the life of their mature (off patent) products as well as to develop new markets for their ethical (patented) products.

“The emergence of a middle class with growing disposable incomes in rapidly expanding countries with large populations, such as Brazil, Russia, India, China, Korea, Mexico, represents tens of millions of new customers, who will demand improved healthcare. Executives surveyed discussed the importance of having an emerging market strategy and many mentioned that their companies have extensive expansion plans underway to increase market share in emerging markets,” the report said.

Highlighting the importance of emerging markets, Hitesh Sharma, national leader & partner, healthsciences practice, Ernst & Young India said: "Growth in emerging markets like India will play a key role in current times for the pharma industry. Companies need to consider how they increase the speed of change by prioritizing, allocating resources effectively and exercising rigor in project management. The finance function and risk and control functions will take a more prominent role and will be tasked with driving more sophisticated financial strategies more specifically targeted on value creation.”

According to the study, pharmaceutical executives are exploring more strategic and sustainable approaches to create lasting cost advantages. “They aim to rely less on cost-cutting campaigns that ignore or imperil long-term growth plans. Only 40 per cent of executives ranked optimizing costs as their most important initiative, compared to a similar study in 2007 in which 92 per cent of executives ranked cost reduction as their number one initiative,” the report said.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 13 2008 | 5:52 PM IST

Next Story